Commonwealth Equity Services
VERV

Commonwealth Equity Services’s Verve Therapeutics VERV Stock Holding History

Commonwealth Equity Services’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-32,954
Closed -$370K – 4441
2025
Q2 		$370K Buy
32,954
+928
+3% +$5.29K ﹤0.01% 3413
2025
Q1 		$146K Buy
32,026
+74
+0.2% +$496 ﹤0.01% 3925
2024
Q4 		$180K Buy
31,952
+4,785
+18% +$27K ﹤0.01% 3800
2024
Q3 		$131K Sell
27,167
-791
-3% -$4.59K ﹤0.01% 3817
2024
Q2 		$136K Buy
27,958
+357
+1% +$2.24K ﹤0.01% 3757
2024
Q1 		$367K Buy
27,601
+15,116
+121% +$200K ﹤0.01% 3088
2023
Q4 		$174K Buy
+12,485
New +$155K ﹤0.01% 3561

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Commonwealth Equity Services's VERV Position: Q3 2025 in Review

Commonwealth Equity Services sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 32,954 shares — an estimated $370K sold.

Commonwealth Equity Services first reported a position in VERV in Q4 2023 and held it in 7 quarters. The position peaked at $370K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Commonwealth Equity Services reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Commonwealth Equity Services sold 32,954 Verve Therapeutics shares in Q3 2025, an estimated $370K.
  • Commonwealth Equity Services first reported a position in Verve Therapeutics in Q4 2023 and held it in 7 quarters.
  • Commonwealth Equity Services's Verve Therapeutics position peaked at $370K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Commonwealth Equity Services's 13F filing for Q3 2025, filed 22 Oct 2025.